表紙
市場調查報告書

依賴ATP的RNA解旋酸DDX58:開發中產品分析

Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 371016
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
依賴ATP的RNA解旋酸DDX58:開發中產品分析 Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 64 Pages
簡介

本報告提供以依賴ATP的RNA解旋酸DDX58為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

依賴ATP的RNA解旋酸DDX58 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Rigontec GmbH
  • Spring Bank Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2188TDB

Summary

According to the recently published report 'Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019'; Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - RIG-I (retinoic acid-inducible gene 1) is a RIG-I-like receptor dsRNA helicase enzyme encoded by the DDX58 gene. It is involved in viral double-stranded (ds) RNA recognition and the regulation of immune response. It acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and proinflammatory cytokines.

The report 'Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019' outlays comprehensive information on the Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Hepatitis B, Solid Tumor, Breast Cancer, Lymphoma, Melanoma, Metastatic Liver Cancer, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors and Triple-Negative Breast Cancer (TNBC).

Scope

  • The report provides a snapshot of the global therapeutic landscape for Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)
  • The report reviews Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Overview
  • Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Companies Involved in Therapeutics Development
  • Bioncotech Therapeutics SL
  • Kineta Inc
  • Merck & Co Inc
  • Sirenas LLC
  • Spring Bank Pharmaceuticals Inc
  • Vycellix Inc
  • Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Drug Profiles
  • (inarigivir soproxil + tenofovir disoproxil fumarate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antisense RNAi Oligonucleotide to Agonize RIG1 for Solid Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BO-112 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • inarigivir soproxil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KIN-1312 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MK-4621 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SB-44 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SB-9400 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SLR-20 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Modulate RIG-I for Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Target RIG-I for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VY-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VY-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Dormant Products
  • Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 12, 2019: Bioncotech Therapeutics phase I BO-112 data presented at ESMO Immuno-Oncology Congress 2019
  • Oct 17, 2019: Spring Bank announces interim top-line results from the first cohort of the phase 2 trial evaluating low-dose Inarigivir plus Vemlidy in Chronic Hepatitis B Patients
  • Oct 14, 2019: A Yale-developed drug shows promise as immune therapy for cancer
  • Jun 06, 2019: Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg
  • Apr 12, 2019: Spring Bank announces positive results from the recently completed phase 2 chronic hepatitis B ACHIEVE Trial and additional Inarigivir studies
  • Apr 10, 2019: Spring Bank to host a conference call to discuss Inarigivir data presented at the International Liver Congress (EASL 2019)
  • Mar 28, 2019: Spring Bank announces Inarigivir abstracts accepted for oral and poster presentations at The International Liver Congress (EASL 2019)
  • Nov 09, 2018: Spring Bank announces additional Inarigivir results at AASLD Conference
  • Oct 09, 2018: Merck to present data on tumor drug candidate MK-4621 at ESMO 2018
  • Oct 03, 2018: Spring Bank announces Inarigivir data presentations at AASLD Conference
  • Aug 02, 2018: Spring Bank announces positive study results from the Inarigivir ACHIEVE trial
  • Apr 10, 2018: Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress
  • Mar 14, 2018: Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
  • Nov 15, 2017: Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
  • Oct 20, 2017: Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Bioncotech Therapeutics SL, H2 2019
  • Pipeline by Kineta Inc, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Sirenas LLC, H2 2019
  • Pipeline by Spring Bank Pharmaceuticals Inc, H2 2019
  • Pipeline by Vycellix Inc, H2 2019
  • Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top